Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of intravenous versus intraperitoneal bevacizumab in malignant ascites
NL-OMON32123Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab in malignant ascites (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Pharmacokinetics of intravenous and intraperitoneal 111In-bevacizumab. Started Jun 2009; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NL-OMON32123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32123.